摘要
目的:分析吉非替尼治疗非小细胞肺癌的临床疗效。方法:调查我院2005年1月到2006年12月患非小细胞肺癌的住院病人40例,给予吉非替尼250 mg,每日1次口服。结果:总有效率为35.0%(完全缓解1例,部分缓解13例),疾病控制率为82.5%(完全缓解1例,部分缓解13例,基本稳定19例)。其中男性病人29例,女性病人11例,有效率分别为55.2%和36.4%(P<0.05)。主要不良反应是恶心呕吐37%、厌食25%、皮疹18%等。结论:吉非替尼治疗非小细胞肺癌有较好的疗效,不良反应较轻,可以提高大多数病人的生活和生存质量。
Objective：To analyze clinical curative effect of Gefitinib to treat NSCLC （non-small cell lung cancer）. Methods：40 eases in-patient with NSCLC in Hospital of PLA General Hospital during Juan 2005 to Dec 2006,were administrated Gefitinib 250 mg daily orally, and investigated for it＇ s curative effect. Results：The total effective rate was 35.0% , CR （complete remission ） 1 case,PR （partial remission） 13 cases,the disease control rate was 82.5% （ CR was 1 case,PR was 13 cases,basio-stabilization was 19 eases）. There were 29 male patients and 11 females,and effective rate were 55.2% and 36.4% respectively （ P 〈 0.05 ）. The main adverse reaction were nausea and vomiting （37%） , anorexy （25%） , and exanthem （ 18% ）. Conclusion： Gefitinib has a better curative effect to treat NSCLC,and the adverse effect is gently,it can improve majority patient quality of life and survival.
出处
《药学实践杂志》
CAS
2007年第6期399-400,共2页
Journal of Pharmaceutical Practice
关键词
吉非替尼
非小细胞肺癌
疗效分析
Gefitinib non-small cell lung cancer（NSCLC）
clinical curative effect analysis
作者简介
贾国强（1973-），男，主管药师，Tel：（010）66937604，13651393006．E-mail：jiagq0825@sina．com．
